PROVIDING ALZHEIMER S FRIENDLY ENVIRONMENT PATRONS

Brand	Owner	Address	Description
ALZHEIMER'S FRIENDLY BUSINESS	HOME INSTEAD, INC.	13323 California Street Omaha NE 68154	providing Alzheimer's-friendly environment for patrons;The certification mark, as intended to be used by businesses authorized by the certifier, is intended to certify that the business using the mark has successfully completed certifier's specialized training in the fields of Alzheimer's disease and other dementias, and that such business has committed to rendering its services in a manner that is consistent with the related best practices highlighted by such training. used by persons authorized by the certifier, is intended to certify that the business using the mark has met certain minimum formal education standards, maintains current certification or licensure in their healthcare field, and has met experience standards in the fields of Alzheimer's disease and dementia, and that the work in rendering the services was performed by persons who have met the standards and criteria established by the certifier.;
	Where the owner name is not linked, that owner no longer owns the brand

Technical Examples

The construction of transgenic animal models of human Alzheimer's disease, and methods of using the models to screen potential Alzhe## disease therapeutics, are described. The models are characterized by pathologies similar to pathologies observed in Alzheimer's disease, based on expression of all three forms of the ?-amyloid precursor protein (APP), APP695, APP751, and APP770, as well as various point mutations based on naturally occurring mutations, such as the London and Indiana familial Alzheimer's disease (FAD) mutations at amino acid 717, predicted mutations in the APP gene, and truncated forms of APP that contain the A? region. Animal cells can be isolated from the transgenic animals or prepared using the same constructs with standard techniques such as lipofection or electroporation. The transgenic animals, or animal cells, are used to screen for compounds altering the pathological course of Alzheimer's disease as measured by their effect on the amount of APP, ?-amyloid peptide, and numerous other Alzheimer's disease markers in the animals, the neuropathology of the animals, as well as by behavioral alterations in the animals.